Literature DB >> 24074568

Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN.

Kabamba B Alexandre1, Penny L Moore, Molati Nonyane, Elin S Gray, Nthabeleng Ranchobe, Ereck Chakauya, James B McMahon, Barry R O'Keefe, Rachel Chikwamba, Lynn Morris.   

Abstract

We examined the ability of HIV-1 subtype C to develop resistance to the inhibitory lectins, griffithsin (GRFT), cyanovirin-N (CV-N) and scytovirin (SVN), which bind multiple mannose-rich glycans on gp120. Four primary HIV-1 strains cultured under escalating concentrations of these lectins became increasingly resistant tolerating 2 to 12 times their 50% inhibitory concentrations. Sequence analysis of gp120 showed that most had deletions of 1 to 5 mannose-rich glycans. Glycosylation sites at positions 230, 234, 241, 289 located in the C2 region and 339, 392 and 448 in the C3-C4 region were affected. Furthermore, deletions and insertions of up to 5 amino acids in the V4 region were observed in 3 of the 4 isolates. These data suggest that loss of glycosylation sites on gp120 as well as rearrangement of glycans in V4 are mechanisms involved in HIV-1 subtype C escape from GRFT, CV-N and SVN.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cyanovirin-N; Entry inhibitor; Glycans; Griffithsin; HIV subtype C; Microbicide; Resistance; Scytovirin; Single genome amplification

Mesh:

Substances:

Year:  2013        PMID: 24074568      PMCID: PMC3787538          DOI: 10.1016/j.virol.2013.07.019

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  52 in total

1.  Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells.

Authors:  X Zhu; C Borchers; R J Bienstock; K B Tomer
Journal:  Biochemistry       Date:  2000-09-19       Impact factor: 3.162

2.  A potent novel anti-HIV protein from the cultured cyanobacterium Scytonema varium.

Authors:  Heidi R Bokesch; Barry R O'Keefe; Tawnya C McKee; Lewis K Pannell; Gregory M L Patterson; Roberta S Gardella; Raymond C Sowder; Jim Turpin; Karen Watson; Robert W Buckheit; Michael R Boyd
Journal:  Biochemistry       Date:  2003-03-11       Impact factor: 3.162

3.  Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1.

Authors:  James Lue; Mayla Hsu; David Yang; Preston Marx; Zhiwei Chen; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

4.  Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.

Authors:  B Losman; A Bolmstedt; K Schønning; C Westin; E M Fenyö; S Olofsson
Journal:  AIDS Res Hum Retroviruses       Date:  2001-07-20       Impact factor: 2.205

5.  Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.

Authors:  Renata Bures; Lynn Morris; Carolyn Williamson; Gita Ramjee; Mark Deers; Susan A Fiscus; Salim Abdool-Karim; David C Montefiori
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

6.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

7.  Characterization and selection of HIV-1 subtype C isolates for use in vaccine development.

Authors:  Carolyn Williamson; Lynn Morris; Maureen F Maughan; Li-Hua Ping; Sergey A Dryga; Robin Thomas; Elizabeth A Reap; Tonie Cilliers; Joanne van Harmelen; Alvaro Pascual; Gita Ramjee; Glenda Gray; Robert Johnston; Salim Abdool Karim; Ronald Swanstrom
Journal:  AIDS Res Hum Retroviruses       Date:  2003-02       Impact factor: 2.205

8.  The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C.

Authors:  Tonie Cilliers; Jabulani Nhlapo; Mia Coetzer; Dragana Orlovic; Thomas Ketas; William C Olson; John P Moore; Alexandra Trkola; Lynn Morris
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

9.  Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR.

Authors:  George Lin; Graham Simmons; Stefan Pöhlmann; Frédéric Baribaud; Houping Ni; George J Leslie; Beth S Haggarty; Paul Bates; Drew Weissman; James A Hoxie; Robert W Doms
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

10.  Broad neutralization coverage of HIV by multiple highly potent antibodies.

Authors:  Laura M Walker; Michael Huber; Katie J Doores; Emilia Falkowska; Robert Pejchal; Jean-Philippe Julien; Sheng-Kai Wang; Alejandra Ramos; Po-Ying Chan-Hui; Matthew Moyle; Jennifer L Mitcham; Phillip W Hammond; Ole A Olsen; Pham Phung; Steven Fling; Chi-Huey Wong; Sanjay Phogat; Terri Wrin; Melissa D Simek; Wayne C Koff; Ian A Wilson; Dennis R Burton; Pascal Poignard
Journal:  Nature       Date:  2011-09-22       Impact factor: 49.962

View more
  14 in total

Review 1.  HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.

Authors:  Priyamvada Acharya; Sabrina Lusvarghi; Carole A Bewley; Peter D Kwong
Journal:  Expert Opin Ther Targets       Date:  2015-02-27       Impact factor: 6.902

2.  Griffithsin Retains Anti-HIV-1 Potency with Changes in gp120 Glycosylation and Complements Broadly Neutralizing Antibodies PGT121 and PGT126.

Authors:  Kathryn Fischer; Kimberly Nguyen; Patricia J LiWang
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

3.  Sustained-release Griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infections.

Authors:  Kevin M Tyo; Amanda B Lasnik; Longyun Zhang; Mohamed Mahmoud; Alfred B Jenson; Joshua L Fuqua; Kenneth E Palmer; Jill M Steinbach-Rankins
Journal:  J Control Release       Date:  2020-02-05       Impact factor: 9.776

4.  Binding Site Geometry and Subdomain Valency Control Effects of Neutralizing Lectins on HIV-1 Viral Particles.

Authors:  Sabrina Lusvarghi; Katheryn Lohith; Jeanne Morin-Leisk; Rodolfo Ghirlando; Jenny E Hinshaw; Carole A Bewley
Journal:  ACS Infect Dis       Date:  2016-10-03       Impact factor: 5.084

5.  Cyanovirin-N produced in rice endosperm offers effective pre-exposure prophylaxis against HIV-1BaL infection in vitro.

Authors:  E Vamvaka; A Evans; K Ramessar; L R H Krumpe; R J Shattock; B R O'Keefe; P Christou; T Capell
Journal:  Plant Cell Rep       Date:  2016-03-23       Impact factor: 4.570

Review 6.  Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential.

Authors:  Sabrina Lusvarghi; Carole A Bewley
Journal:  Viruses       Date:  2016-10-24       Impact factor: 5.048

Review 7.  Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41.

Authors:  Jing Pu; Qian Wang; Wei Xu; Lu Lu; Shibo Jiang
Journal:  Viruses       Date:  2019-08-01       Impact factor: 5.048

8.  Engineering of a Lectibody Targeting High-Mannose-Type Glycans of the HIV Envelope.

Authors:  Krystal Teasley Hamorsky; J Calvin Kouokam; Matthew W Dent; Tiffany N Grooms; Adam S Husk; Steven D Hume; Kenneth A Rogers; Francois Villinger; Mary Kate Morris; Carl V Hanson; Nobuyuki Matoba
Journal:  Mol Ther       Date:  2019-08-09       Impact factor: 11.454

9.  HIV-1 Envelope Glycan Composition as a Key Determinant of Efficient Virus Transmission via DC-SIGN and Resistance to Inhibitory Lectins.

Authors:  Muzafar Jan; Chitra Upadhyay; Catarina E Hioe
Journal:  iScience       Date:  2019-10-18

10.  Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV infections in vivo.

Authors:  Nina Derby; Manjari Lal; Meropi Aravantinou; Larisa Kizima; Patrick Barnable; Aixa Rodriguez; Manshun Lai; Asa Wesenberg; Shweta Ugaonkar; Keith Levendosky; Olga Mizenina; Kyle Kleinbeck; Jeffrey D Lifson; M Melissa Peet; Zachary Lloyd; Michael Benson; Walid Heneine; Barry R O'Keefe; Melissa Robbiani; Elena Martinelli; Brooke Grasperge; James Blanchard; Agegnehu Gettie; Natalia Teleshova; José A Fernández-Romero; Thomas M Zydowsky
Journal:  Nat Commun       Date:  2018-09-24       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.